Elan reaffirms commitment to Tysabri

Pharmaceutical giant Elan is to press ahead with the development of its landmark MS drug Tysabri, it was announced today.

“In response to Biogen Idec Inc’s announcement on December 12, 2007 that it has completed its strategic review and will continue its present course as an independent company, Elan Corporation plc today reaffirmed its commitment to Tysabri and the patients who are and will benefit from this treatment,” the company said a statement.